Article Text


Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations

Statistics from

OpenUrlCrossRefPubMedWeb of Science

Q In patients with asthma, is budesonide (BUD) plus formoterol (FORM) (BUDFORM) for both maintenance and symptom relief more effective than fixed dosing using BUDFORM or a 4 fold higher dose of BUD, both with a short acting β2 agonist (SABA), for reducing the rate of severe asthma exacerbations?


Embedded ImageDesign:

randomised controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded (patients and healthcare providers).

Embedded ImageFollow up period:

1 year

Embedded ImageSetting:

246 centres in 22 countries.

Embedded ImagePatients:

2760 outpatients (mean age 36 y, 55% women/girls; 12% children 4–11 y) with asthma who were using inhaled corticosteroids (ICSs).

Embedded ImageIntervention:

BUDFORM (BUD, 80 μg plus FORM, 4.5 μg) both for …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.